Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pentacel: HCPDT-IPV/PRP-T Vaccine and Prevnar · 1 trial · 5 indications
Seroconversion was defined as the percentage of subjects with ≥ 4-fold post-dose 3 for anti-pertussis and ≥ 0.15 μg/mL or ≥ 1.0 μg/mL for anti-Polyribosylribitol Phosphate (PRP) responses.
Anti-pertussis response include antibodies to Pertussis Toxoid (PT); Filamentous Haemagglutinin (FHA); Fimbriae Types 2 and 3 (FIM) and Pertactin (PRN) antigens.
| Arm | Type | Description |
|---|---|---|
| Pentacel™ concurrently with Prevnar® | EXPERIMENTAL | Participants had Pentacel™ concurrently administered with Prevnar® |
| Pentacel™ staggered schedule with Prevnar® | EXPERIMENTAL | Participants had Pentacel™ given at different times from Prevnar® (using a standardized, staggered schedule). |
| Name | Type | Description |
|---|---|---|
| Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar® | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria : * Healthy infants 2 months (≥ 42 days and ≤ 89 days) of age. * Infants with at least 36 weeks of gestation at delivery. * Must have received 1 dose of Hepatitis B vaccine (with that dose at least 15 days before the administration of study vaccines). * Able to attend the schedul...
Pentacel is a combination vaccine developed by Sanofi for protection against diphtheria, tetanus, Haemophilus influenzae infection, pertussis, and polio. It is studied alongside Prevnar, a pneumococcal conjugate vaccine. The asset is in Phase 3 clinical development for diphtheria and related infectious diseases.
Pentacel is used for immunization against diphtheria, tetanus, Haemophilus influenzae infection, pertussis, and polio. Prevnar is a pneumococcal conjugate vaccine studied in combination with Pentacel. The Phase 3 trial evaluated the effect of Prevnar on the immunogenicity of Pentacel in healthy volunteers.
Sanofi develops Pentacel: HCPDT-IPV/PRP-T Vaccine and Prevnar. Sanofi trades on the New York Stock Exchange under the ticker SNY. The company is the sponsor of the Phase 3 study evaluating the combination.
Pentacel: HCPDT-IPV/PRP-T Vaccine and Prevnar is in Phase 3 clinical development. The single completed trial, NCT00772928, was a Phase 3 study. The asset is investigational and has not been approved by the FDA for the studied indication.
Pentacel: HCPDT-IPV/PRP-T Vaccine and Prevnar has been studied in one completed Phase 3 trial, NCT00772928, titled Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel. The trial enrolled 1,167 participants in the United States and included healthy volunteers aged 42 days and older.
Pentacel: HCPDT-IPV/PRP-T Vaccine and Prevnar is also known as Pentacel: HCPDT-IPV//PRP-T Vaccine and Prevnar. The names refer to the same combination vaccine asset developed by Sanofi. The alternative spelling uses a double slash between HCPDT-IPV and PRP-T.